NCT01599936 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Berg RA, Tarantino MD
Envenomation by the scorpion Centruroides exilicauda (C sculpturatus): severe and unusual manifestations. Pediatrics. 1991 Jun;87(6):930-3.
Boyer LV, Theodorou AA, Berg RA, Mallie J; Arizona Envenomation Investigators, Chávez-Méndez A, García-Ubbelohde W, Hardiman S, Alagón A
Antivenom for critically ill children with neurotoxicity from scorpion stings. N Engl J Med. 2009 May 14;360(20):2090-8. doi: 10.1056/NEJMoa0808455.
Curry SC, Vance MV, Ryan PJ, Kunkel DB, Northey WT
Envenomation by the scorpion Centruroides sculpturatus. J Toxicol Clin Toxicol. 1983-1984;21(4-5):417-49. Review.
Gibly R, Williams M, Walter FG, McNally J, Conroy C, Berg RA
Continuous intravenous midazolam infusion for Centruroides exilicauda scorpion envenomation. Ann Emerg Med. 1999 Nov;34(5):620-5.
Likes K, Banner W Jr, Chavez M
Centruroides exilicauda envenomation in Arizona. West J Med. 1984 Nov;141(5):634-7.
LoVecchio F, Welch S, Klemens J, Curry SC, Thomas R
Incidence of immediate and delayed hypersensitivity to Centruroides antivenom. Ann Emerg Med. 1999 Nov;34(5):615-9.

Open Label, Confirmatory, Controlled Clinical Study of Alacramyn® in Pediatric Patients With Scorpion Sting Envenomation

Clinical trial NCT01599936 - References